US4937254A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for inhibiting post-surgical adhesion formation by the topical administration of non-steroidal anti-inflammatory drug
Assignee: EHITHCON Inc A CORP OF NEW JERSEY
•
Filing: 1988-01-26
•
Granted: 1990-06-26
•
Expires: 2008-01-26
Abstract
Abstract Postsurgical adhesion formation is inhibited by the topical administration to the site of surgical trauma of a non-steroidal anti-inflammatory drug, preferably ibuprofen, suprofen, or tolmetin.
Inventors
- 👤 Warren D. Sheffield
- 👤 Douglas B. Johns
- 👤 Shalaby W. Shalaby
- 👤 Gere S. diZerega
- 👤 LeRoy L. Richer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:26
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K31/00; A61K31/185; A61K31/19; A61K31/33; A61K31/38; A61K31/395; A61K31/40; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
61 words
A process for inhibiting post-surgical adhesion formation in mammals which comprises the topical locally effective administration to the injured tissue surface site of surgical trauma of an effective amount of a composition including as an active ingredient a non-steroidal anti-inflammatory drug, such administration beginning after surgery and continuing for a period of time sufficient to inhibit the formation of post-surgical adhesions.
Claim 2
Dependent Claim
61 words
A process for inhibiting post-surgical adhesion formation in mammals which comprises the topical locally effective administration to the injured tissue surface site of surgical trauma of an effective amount of a composition including as an active ingredient a non-steroidal anti-inflammatory drug, such administration beginning after surgery and continuing for a period of time sufficient to inhibit the formation of post-surgical adhesions.
Claim 3
Dependent Claim
19 words
The process of claim 1 wherein the active ingredient is ibuprofen or a pharmaceutically acceptable salt or ester thereof.
Claim 4
Dependent Claim
19 words
The process of claim 1 wherein the active ingredient is suprofen or a pharmaceutically acceptable salt or ester thereof.
Claim 5
Dependent Claim
19 words
The process of claim 1 wherein the active ingredient is tolmetin or a pharmaceutically acceptable salt or ester thereof.
Claim 6
Dependent Claim
20 words
The process of claim 1 wherein said sterile composition includes hyaluronic acid or a pharmaceutically acceptable salt or ester thereof.
Claim 7
Dependent Claim
13 words
The process of claim 1 wherein said said sterile composition includes a phospholipid.
Claim 8
Dependent Claim
12 words
The process of claim 6 wherein said phospholipid is a phospholipid vesicle.
Claim 9
Dependent Claim
21 words
The process of claim 6 wherein the sterile composition comprises an aqueous mixture of a phospholipid, an organic acid, and tolmetin.
Claim 10
Dependent Claim
17 words
The process of claim 8 wherein said organic acid is ascorbic acid, lactic acid, or citric acid.
Claim 11
Dependent Claim
33 words
The process of claim 1 wherein said non-steroidal anti-inflammatory drug is contained in a controlled release carrier that released said drug over said period of time, wherein said carrier is an absorbable polymer.
Claim 12
Dependent Claim
25 words
The process of claim 10 wherein said absorbable polymer is a homopolymer or copolymer of lactic acid, glycolic acid, their cyclic dimer esters, or p-dioxanone.
Claim 13
Dependent Claim
14 words
The process of claim 11 wherein said polymer is in the form of microcapsules.
Claim 14
Dependent Claim
29 words
The process of claim 12 wherein said microcapsules include lecithin in an amount sufficient to enhance the ability of said microcapsules to adhere to the site of surgical trauma.
Claim 15
Dependent Claim
18 words
The process of claim 1 wherein the sterile composition comprises an aqueous composition including a surface active agent.
Claim 16
Dependent Claim
17 words
The process of claim 14 wherein the aqueous composition comprises an aqueous solution of ethoxylated sorbitan mono-oleate.
Claim 17
Dependent Claim
35 words
The process of claim 1 wherein said sterile composition is administered in a single dose, and wherein the concentration of active ingredient in said composition is at least about 0.025 to 5 milligrams per milliliter.
Claim 18
Dependent Claim
36 words
The process of claim 1 wherein said composition is administered continually over said period of time, and wherein the concentration of active ingredient in said composition is at least about 0.01 to 10 milligrams per milliliter.
Claim 19
Dependent Claim
14 words
A sterile aqueous composition including a surface active agent and a non-steroidal anti-inflammatory drug.
Claim 20
Dependent Claim
14 words
A sterile aqueous composition including a surface active agent and a non-steroidal anti-inflammatory drug.
Claim 21
Dependent Claim
21 words
The sterile composition of claim 18 wherein the drug is ibuprofen, suprofen, tolmetin, or a pharmaceutically acceptable salt or ester thereof.
Claim 22
Dependent Claim
13 words
A sterile composition comprising an absorbable polymer microcapsule containing a non-steroidal anti-inflammatory drug.
Claim 23
Dependent Claim
13 words
A sterile composition comprising an absorbable polymer microcapsule containing a non-steroidal anti-inflammatory drug.
Claim 24
Dependent Claim
18 words
The composition of claim 20 wherein the polymer is a homopolymer or copolymer of lactide, glycolide, or P-dioxanone.
Claim 25
Dependent Claim
20 words
The composition of claim 21 wherein the drug is ibuprofen, suprofen, tolmetin, or a pharmaceutically acceptable salt or ester thereof.
Claim 26
Dependent Claim
29 words
A sterile composition comprising an aqueous composition containing hyaluronic acid or pharmaceutically acceptable salt or ester thereof and a non-steroidal anti-inflammatory drug or pharmaceutically acceptable salt or ester thereof.
Claim 27
Dependent Claim
29 words
A sterile composition comprising an aqueous composition containing hyaluronic acid or pharmaceutically acceptable salt or ester thereof and a non-steroidal anti-inflammatory drug or pharmaceutically acceptable salt or ester thereof.
Claim 28
Dependent Claim
20 words
The sterile composition of claim 23 wherein the non-steroidal anti-inflammatory drug is tolmetin or pharmaceutically acceptable salt or ester thereof.
References Cited (Backward Citations)
US3755558A
Cited
US4141973A
Cited
US4141973B1
Cited
US4427649A
Cited
US4166800A
Cited
US4240163A
Cited
US4337251A
Cited
US4389330A
Cited
US4346108A
Cited
US4485088A
Cited
US4522803A
Cited
US4517295A
Cited
US4474753A
Cited
US4478822A
Cited
US4474751A
Cited
US4474752A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-25 | 1993-12-25 | 1994-06-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-25 | 1997-12-25 | 1998-06-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-25 | 2001-12-25 | 2002-06-26 | $7700.00 | Window Closed / Lapsed |